How Fast Does Methotrexate Work? Timeline Explained

Methotrexate typically takes weeks to months to produce noticeable improvement, with the exact timeline depending heavily on the condition being treated. For rheumatoid arthritis, most guidelines suggest allowing at least three months before expecting a meaningful response, and a full six months before judging whether the drug is truly working. For ectopic pregnancy, a completely different use, resolution usually happens within three to five weeks. The gap between those timelines reflects fundamentally different ways methotrexate acts in the body, and understanding the expected pace for your specific condition can save you from abandoning a treatment too early or sticking with one too long.

Rheumatoid Arthritis and Inflammatory Arthritis

Rheumatoid arthritis is the condition most commonly treated with methotrexate, and it is also where the “slow burn” nature of the drug is most apparent. Expert recommendations call for continuing oral methotrexate, with appropriate dose adjustments, for at least six months before making a definitive call on whether it works for you, provided you see at least some improvement within the first three months.¹ A Cochrane review of the evidence concluded that twelve weeks is the minimum treatment duration needed to adequately assess methotrexate’s efficacy in rheumatoid arthritis.²

In practical terms, many people notice some reduction in joint swelling and morning stiffness around four to six weeks after starting. But that early improvement is often partial. The drug continues building its effect over months, and the difference between week six and week twenty-four can be substantial. If you feel only marginally better at week eight, that does not mean methotrexate has failed; the drug may simply not have reached its full potential yet.

Psoriasis and Psoriatic Arthritis

Data from the tight-control psoriatic arthritis study (TICOPA) gives a useful snapshot of where patients stand after about three months on methotrexate. At twelve weeks, roughly 41% of patients achieved at least a 20% improvement in their arthritis symptoms, about 19% reached 50% improvement, and around 9% hit 70% improvement. For the skin component, about 27% of patients reached a 75% reduction in their psoriasis severity score.³ Those numbers tell you two things: methotrexate does work for psoriatic arthritis, but at three months a majority of patients have not yet reached the targets clinicians aim for. Continued treatment and dose optimization often push response rates higher.

Skin-predominant psoriasis follows a loosely similar trajectory. Clearing tends to start somewhere in the first month or two, but reaching meaningful plaque clearance often takes three months or longer. The route of delivery matters here too, which is covered further below.

Crohn’s Disease and Inflammatory Bowel Disease

In Crohn’s disease, methotrexate occupies a middle lane between drugs that act quickly and those that take even longer. A landmark trial using intramuscular methotrexate at 25 mg per week found that after sixteen weeks, about 39% of patients were in clinical remission compared with 19% on placebo.⁴ In children with Crohn’s, a smaller study reported a median time to remission of twelve weeks.⁵

A review of treatment timelines across inflammatory bowel disease therapies grouped methotrexate alongside thiopurines and vedolizumab as medications that take several months to reach maximal efficacy.⁶ If your gastroenterologist starts you on methotrexate for Crohn’s, expect the first clear signs of benefit around two to four months, with the understanding that it can continue improving beyond that window.

Ectopic Pregnancy

This is the one common use of methotrexate where the timeline is measured in days and weeks rather than months. When used for tubal ectopic pregnancy, methotrexate works by stopping the rapidly dividing pregnancy tissue from growing, allowing the body to reabsorb it. A retrospective study of women treated with methotrexate for ectopic pregnancy found a median time to resolution of about 22 days, though the range was wide. Women with lower initial hCG levels resolved faster, with a median around 20 days when hCG was below 1,000 IU/L, rising to about 32 days when hCG was between 1,000 and 2,000, and about 35 days for levels between 2,000 and 3,000.⁷

The early trend in hCG levels after the injection is a strong predictor. Women whose hCG dropped within the first four days resolved in a median of 21 days, while those whose hCG rose by a large amount sometimes took over two months and were at much higher risk of needing surgical intervention.⁷ A separate study found that initial hCG values above roughly 1,360 mIU/mL were a threshold associated with treatment failure.⁸ Your doctor will monitor hCG levels at specific intervals after the injection, and those numbers tell the story of whether the treatment is working.

Why the Drug Takes So Long for Inflammatory Conditions

The reason methotrexate takes weeks or months to control arthritis, psoriasis, or Crohn’s disease has to do with how it quiets inflammation. At the low doses used for autoimmune conditions, methotrexate does not simply kill cells the way it does in cancer chemotherapy. Instead, it triggers a chain of events inside cells that leads to increased release of adenosine, a natural molecule that acts as an anti-inflammatory signal. Methotrexate gets converted inside cells into polyglutamate forms that accumulate over time, and these polyglutamates block an enzyme called ATIC, causing a buildup of a precursor molecule that eventually boosts adenosine levels at inflamed sites.⁹ That adenosine then binds to specific receptors on immune cells, dampening the inflammatory response.¹⁰

The key point for understanding the timeline is that those polyglutamate forms need to accumulate in your cells to reach effective concentrations. This does not happen overnight. Each weekly dose adds a little more to the intracellular pool, and it takes repeated doses over weeks for that pool to reach a level that meaningfully shifts your inflammatory balance. Animal studies confirmed that the anti-inflammatory effect depends on the adenosine pathway working extracellularly, which requires sufficient polyglutamate buildup inside cells to push the process along.¹¹

Does Subcutaneous Methotrexate Work Faster Than Oral?

There is a reasonable case that injecting methotrexate under the skin gets it working somewhat sooner than swallowing it as a pill. Pharmacokinetic studies show that subcutaneous methotrexate delivers higher blood levels and leads to faster initial accumulation of the active polyglutamate forms inside red blood cells. Over time, though, intracellular drug levels tend to even out between the two routes.¹²

In psoriasis, the difference can be clinically meaningful. One head-to-head comparison found dramatically higher clearance rates with subcutaneous methotrexate: about 57% of patients on injections achieved a 90% skin improvement score compared with only 7% on oral tablets. Subcutaneous delivery also offers more predictable absorption, particularly at doses above 15 mg per week, where the gut’s ability to absorb oral methotrexate plateaus.¹³ If you have been on oral methotrexate for a few months with a tepid response, switching to injections is one of the first strategies your doctor might try before moving to a different drug altogether.

Does Ramping Up the Dose Faster Speed Things Along?

It seems intuitive that escalating to a higher dose quickly would get you to a therapeutic level sooner. A randomized trial tested exactly this, comparing a fast dose escalation strategy against the usual gradual approach in patients with active rheumatoid arthritis. At sixteen weeks, response rates were essentially identical: about 28% in the usual escalation group and 23% in the fast escalation group achieved a good response, with no meaningful difference in disease activity scores at eight, sixteen, or even twenty-four weeks.¹⁴ Ramping up faster did not translate into faster results. This reinforces the idea that the drug’s timeline is governed more by how quickly polyglutamates accumulate inside cells than by how much drug you take in any given week.

Bridging with Steroids While You Wait

Because methotrexate takes so long to kick in, doctors often prescribe corticosteroids as a “bridge” to control symptoms during those first few months. Two different bridging strategies were compared in early arthritis: a higher-dose prednisone taper that started at 60 mg daily and was reduced over seven weeks, versus a lower-dose approach starting at 15 mg daily tapered to nothing over ten weeks. The higher-dose taper was associated with better early clinical outcomes, though it came with slightly more blood pressure and blood sugar elevations.¹⁵ Either way, the steroid bridge is not a substitute for methotrexate; it simply keeps you comfortable while the methotrexate catches up.

The Folic Acid Trade-Off

Almost everyone on methotrexate for an inflammatory condition takes folic acid supplements to reduce side effects like nausea and mouth sores. There is a wrinkle, though. A study in psoriasis patients found that folic acid supplementation during the early phase of treatment reduced methotrexate’s skin-clearing effect, regardless of whether the patient’s folate levels were normal or low to begin with.¹⁶ This does not mean you should skip folic acid, since the side effects it prevents can be treatment-limiting. But it helps explain why some patients feel like the drug is working more slowly than expected: the very supplement that makes the drug tolerable may blunt part of its effect during the early weeks.

Interestingly, old animal research on folinic acid (a more active form of folate) showed that giving it eight hours after methotrexate protected against toxicity but barely affected methotrexate’s ability to suppress the immune response.¹⁷ This is why most prescribers advise taking folic acid on a different day than your methotrexate dose: timing the two apart may help preserve the drug’s efficacy while still offering protection against side effects.

Why Some People Respond Faster or Slower

Not everyone on the same dose of methotrexate will respond at the same speed, and genetics plays a genuine role. Variations in genes that control how methotrexate is transported into cells, converted to its active polyglutamate forms, and eventually cleared can all shift the timeline. A systematic review of predictive biomarkers identified a range of proteins, metabolites, and immune cell markers measured before treatment that correlated with whether patients would respond well.¹⁸

At the genetic level, variations in the MTHFR gene are among the most studied. Multiple studies have identified specific MTHFR variants associated with how well patients respond to methotrexate, along with variants in genes involved in drug transport like ABCC1 and SLC19A1.¹⁹ Variants in the DHFR gene, which codes for one of the enzymes methotrexate directly inhibits, have also been linked to treatment outcomes.²⁰ These findings have not yet translated into routine genetic testing before starting methotrexate, but they explain why your neighbor might feel dramatically better in six weeks while you are still waiting at twelve.

Children with Juvenile Arthritis

Methotrexate is one of the most commonly used drugs for juvenile idiopathic arthritis, but the evidence base for exactly how fast it works in children is thinner than in adults. A Cochrane review that pooled data from two small trials involving 165 patients under 18 found that methotrexate produced small to moderate improvements in disability, joint range of motion, and measures of disease activity, with improvements ranging from about 3 to 23% better than placebo.²¹ The clinical expectation among pediatric rheumatologists is similar to that in adults: give it at least three months, with a fuller picture emerging closer to six months.

What Happens When You Stop

Because methotrexate works by maintaining a steady pool of active drug inside your cells, what happens when you pause it is informative about how long its effects linger. A post-hoc analysis of two randomized trials examined what happened when rheumatoid arthritis patients on stable methotrexate stopped for either two or four weeks. Pausing for two weeks did not lead to a significant increase in disease activity compared with patients who continued without interruption. However, a four-week pause led to a meaningful rise in disease activity, with about 21% of patients experiencing a flare compared with roughly 7% in the group that kept taking the drug. After methotrexate was restarted, the flare rate evened out between groups again.²²

This tells you something useful about the drug’s effective window. A two-week gap is generally safe, which matters for situations like surgery or vaccinations where temporary discontinuation is sometimes recommended. But by four weeks off the drug, the intracellular polyglutamate pool has dropped enough that inflammation starts creeping back. It also means that when you restart after a longer break, you should expect another lag period before you are back to your previous level of control.